Angiotensin-Converting Enzyme Inhibitor “Lisinopril” Antagonizes Hepatic TGF-β1, improving Hepatic Fibrosis Caused by Experimental Schistosomiasis mansoni | ||||
| Egyptian Academic Journal of Biological Sciences, E. Medical Entomology & Parasitology | ||||
| Volume 15, Issue 1, June 2023, Page 45-59 PDF (1.96 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/eajbse.2023.294651 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Reham R. Mostafa1; Maha H. Elarousy1; Maisa A. Shalaby2; Amany A. Abdelaal3; Soheir S. Mahmoud2; Manal A. Badawi4; Sherif M. Ismail5; Reham K. Nahnoush3 | ||||
| 1Medical Parasitology Department, Faculty of Medicine, Cairo University, Cairo, Egypt. | ||||
| 2Medical Parasitology Department, Theodor Bilharz Research Institute (TBRI), Giza, Egypt. | ||||
| 3Medical Parasitology Department, Faculty of Medicine, Armed Forces College of Medicine (AFCM), Cairo, Egypt. | ||||
| 4Pathology Department, National Research Institute, Giza, Egypt. | ||||
| 5Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt. | ||||
| Abstract | ||||
| Schistosomiasis mansoni leads to liver fibrosis that was believed to be irreversible once established leading to life-threatening complications in most cases. Praziquantel (PZQ) is considered the best drug in treatment, for decades. A universal approach towards drug repurposing is recommended, to be combined with other known drugs that may expand their efficiencies or/and discover new mechanisms of action of the used drugs. In this work Angiotensin-converting enzyme inhibitor (ACEI) “Lisinopril” was used alone or with Praziquantel (PZQ), versus long-duration PZQ (LD-PZQ) to test for their anti-fibrotic properties, applying Transforming Growth factor beta 1 (TGF-β1 ) as an indicator of activated fibrotic fibroblasts, to be automatically quantified within hepatic tissues of experimentally infected mice, using a software image analyzer. All treated groups showed significant reduction within TGF-β1 local hepatic expression, with the greatest reduction occurring among groups treated with LD-PZQ followed by those which received combined ACEI and PZQ. The highest TGF-β1 local hepatic expression values were obtained by groups receiving the classic anti-bilharzial single oral dose praziquantel (S.O.D PZQ) regimen, indicating its ineffectiveness as a monotherapeutic agent to minimize liver fibro-sclerotic threats in acute and chronic phases of schistosomiasis. Lisinopril alone or when combined with PZQ, succeeded in causing a drop in TGF-β1 hepatic expression as LD-PZQ regimen, thus increasing the chance of healing without hepatic scarring. Yet, its usage as an adjuvant to PZQ, instead of LD-PZQ has the additional benefit of not exposing the community to unwarranted resistance to PZQ, a drug that is to date still indispensable for the treatment of bilharziasis. | ||||
| Keywords | ||||
| Lisinopril; Schistosomiasis mansoni; TGF-B1; Hepatic fibrosis | ||||
|
Statistics Article View: 285 PDF Download: 463 |
||||
